Filtered Image?height=270

News & Publications

News & insights

Penningtons Manches Cooper appointed as legal advisor to Advanced Research + Invention Agency (ARIA)
Posted: 28/11/2023
Penningtons Manches Cooper’s Birmingham and Oxford offices have been appointed as legal advisors to the Advanced Research + Invention Agency (ARIA), a new R&D agency built to unlock scientific and technological breakthroughs to benefit everyone.......>>
Sustainability versus patient safety? Navigating the EU’s regulatory framework for medical devices
Posted: 27/11/2023
In recent years environmental, social and governance (ESG) issues have been increasingly prioritised by politicians, industries, and consumers alike, and the pharmaceutical industry is no different. As part of its Net Zero Strategy, the UK government earlier this year set significant carbon reduction targets for the NHS. The ESG drivers for the......>>
Penningtons Manches Cooper advises Imperial University spin-out SPARTA Biodiscovery on fundraise and industry partnership
Posted: 01/11/2023
The corporate team at Penningtons Manches Cooper has advised Imperial University spin-out, SPARTA Biodiscovery, on its partnership and up to £3.5 million funding from international life sciences group, Sartorius. SPARTA Biodiscovery was created to bring novel analytical methods to the development and production of nanoparticles......>>
Penningtons Manches Cooper advises world-leading medical technology company OrganOx on £25 million fundraise
Posted: 04/08/2023
The corporate team at Penningtons Manches Cooper has advised OrganOx on a £25 million growth round led by Lauxera Capital Partners, with support from existing investors. OrganOx is a world-leading medical technology company committed to making every donated organ count with metra, a fully automated normothermic......>>
The state of AI regulation in the UK and EU
Posted: 03/08/2023
On 14 June 2023, the European Parliament overwhelmingly voted to adopt the proposed European Union Artificial Intelligence Act (AI Act). This act aims to regulate in somewhat fine detail the use and development of artificial intelligence (AI) across the EU. The next stage is that trilogue discussions will commence between......>>

Read all Life sciences news & insights

Publications

E-Bulletins

BioBrief - August 2023
In this edition of BioBrief, we look in detail at a recent case involving university-generated intellectual property and in particular the position of students who contribute to such IP. On a related topic, I give some practical, high-level guidance on the legal position relating to the ownership of inventions when outside consultants are involved.

BioBrief - April 2023
Following recent shockwaves throughout the sector caused by the demise of SVB, in this month’s BioBrief, we provide a link to a timely discussion of the funding options for early stage life sciences companies, published by our friends at OBN.

BioBrief - November 2022
A key strategic issue for many seeking partnerships with Big Pharma or other sources of funding is the robustness of the patent portfolio. IP issues feature in two contributions to this month’s BioBrief: in the first, my colleague Dr Amanda Easey and I present a videocast on the recent decision of the Patents Court.

BioBrief - May 2022
Welcome to the spring edition of BioBrief. We start this edition with an article I wrote recently for OBN Connect magazine which covers the challenges faced by Biotech founders on spin-out and the career change it requires. This is something that I am familiar with as I changed my career from project manager of global clinical trials for IQVIA to being an IP lawyer.

BioBrief - Winter 2021
Welcome to the winter edition of BioBrief. It has certainly been a very busy year for the life sciences industry! Colleagues across our team have been involved in interesting projects, in particular in terms of commercial deals and corporate transactions. We are delighted to report that, amongst others, we advised the shareholders of molecular diagnostics company ATDBio on its sale to NASDAQ Stockholm listed Biotage AB for approximately £45m..

View all life sciences e-bulletins

Return to Life sciences

Filter publications

Filter by keyword: Filter by expertise: Filter by publication type:

In this section

Media enquiries

Contact our press team on:

+44 (0)20 7457 3258
+44 (0)7887 888105 (out of hours)

Useful links

Value

Contact an office

London (Head office)
+44 (0)20 7457 3000
Basingstoke
+44 (0)1256 407100
Birmingham
+44 (0)121 312 2560
Cambridge
+44 (0)1223 465465
Guildford
+44 (0)1483 791800
Oxford
+44 (0)1865 722106
Reading
+44 (0)118 982 2640

Madrid
+34 91 781 6670
Paris
+33 1 44 34 24 80
Piraeus
+30 210 361 4840
Singapore
+65 6438 4497

Sectors

Services for Business

Services for Individuals

Copyright

© 2023 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority under number 419867.